| Drug General Information |
| Drug ID |
D06JHV
|
| Former ID |
DIB013320
|
| Drug Name |
Flumatinib
|
| Synonyms |
HH-GV-678
|
| Drug Type |
Small molecular drug
|
| Indication |
Chronic myelogenous leukaemia [ICD9: 205.1; ICD10:C92.1]
|
Phase 2 |
[1]
|
|---|
| Company |
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C29H29F3N8O
|
| Canonical SMILES |
FC(F)(c1cc(C(=O)Nc2cnc(c(c2)Nc2nc(ccn2)c2cnccc2)C)ccc1C<br />N1CCN(CC1)C)F
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Proto-oncogene c-Abl |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Cell cycle
|
|
Axon guidance
|
|
Neurotrophin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
Viral myocarditis
|
|
PANTHER Pathway
|
Axon guidance mediated by Slit/Robo
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
ATM pathway
|
|
Regulation of Telomerase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
PDGFR-beta signaling pathway
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Regulation of actin dynamics for phagocytic cup formation
|
|
CDO in myogenesis
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
HDR through Single Strand Annealing (SSA)
|
|
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by Robo receptor
|
|
Myogenesis
|
|
Factors involved in megakaryocyte development and platelet production
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02511340) A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients. |
|---|
| REF 2 | Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25. |
|---|
